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Introduction 
Diabetes Mellitus (DM) is a group of 
metabolic diseases “resulting from 
defects in insulin secretion, insulin 
action, or both “(McCance, 2014, p. 734). 
• 22 Million people in the USA have 
DM (Pontes et al., 2017) 
• 10-25% of people with DM don’t 
know it (Cornelius, 2016) 
• 7th leading cause of death in the US 
(Cornelius, 2016) 
• $245 Billion in national healthcare 
costs (Cornelius, 2016) 
• DM is the most common medical 
condition and 25% of diabetics will 
need surgery at some point 
(Moningi et al., 2018) 
• DM I decreases life expectancy by 
20 years, DMII by 10 years 
(Cornelius, 2016) 
Because of the prevalence of DM in the 
US, it is imperative that the Nurse 
Anesthetist is knowledgeable about the 
pathophysiology of DM and how that 
may affect anesthetic care. 
Risk Factors 
• Age greater than 45 
• Hypertension 
• Obesity (90% DM patients are 
obese) (Cornelius, 2016) 
• Sedentary lifestyle 
• Familial history 





• Weight loss 




• Blurred Vision 
• Dry skin 
• Slow Healing wounds 
(McGinlay & Mruthunjaya, 2017; CDC, 
2021) 
Figure 2: Type I vs. Type II Diabetes (Horber et al., 2019) 
Autonomic Neuropathy (AN) 
Figure 1: Pathophysiology and Complications of Diabetes (Skyler et al., 2017) 
Significance of Implications for Type I Diabetes Type II Diabetes Conclusions 
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pancreatic islet cells which activate “glycotoxicity, lipotoxicity and 
T helper lymphocytes. amyloid formation” (Pontes et al., • Only 14% of DM pts have no 
• Decreased GI motility  and • The decision to place a comorbidities (Cornelius, 2016) • Activation leads to inflammatory 2017) 
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General Pathophysiology 
• DM is result of the inability of the 
body to properly metabolize fats, 
proteins and carbohydrates, as a 
result  of insufficient insulin or the 
inability to utilize insulin 
(Cornelius, 2016) 
• Lack of insulin leads to 
glycogenesis and glycogenolysis by 
the liver, as well as a reduced 
uptake of glucose. (Levitsky, p.47, 
2021) 
• DM is often seen as a part of 
metabolic syndrome: increased 
triglycerides, insulin resistance, 
obesity, hypertension and 
hyperlipidemia (Levitsky, 2021) 
In states of chronic hyperglycemia, 
glucose combines with free fatty acids. 
Accumulation of these glycation end 
products can lead to microvascular 
complications. (McGinlay & Mruthunjaya, 
2017) 
• Microangiopathic: endothelial 
hyperplasia and thickened capillary 
basement membranes lead to 
vasoconstriction and hypoxia, 
eventually leading to retinopathy, 
nephropathy, neuropathy, etc. 
• Macroangiopathic: atherosclerosis 
and increased risk of blood clots 
(Moningi et al., 2018) 
• Autoimmune destruction of 
pancreatic Beta cells in the Islet of 
Langerhans (McGinlay & 
Mruthunjaya, 2017) 
• Present in approximately 20% of DM 
patients (Cornelius, 2016) 
• “Glycosylation of endoneurial blood 
vessels may cause neural hypoxia, 
resulting in the dysfunction of the 
autonomic nerves of the heart” 
leading to increased risk if silent 
ischemia (Cornelius, 2016) 
• AN can lead to the loss of autonomic 
responses to hypoglycemia (the 
patient will not show classic signs 
and symptoms of hypoglycemia) 
(Pontes et al., 2017) 
of defective insulin secretion 
(McGinlay & Mruthunjaya, 2017) 
AN affecting the vagus nerve  causes: 
1. Unopposed sympathetic nervous 
system (SNS) response leading to 
tachycardia 
2. Impaired SNS response to cardiac 
output 
3. Neurogenic bladder/ erectile 
dysfunction 
4. Anemia from decreased 
erythropoietin production 
5. Gastroparesis 
(Cornelius, 2016; Moningi et al., 2018) 
cardiovascular disorders, 
hypertension, hyperlipidemia, 
chronic kidney disease (CKD), 
depression, sleep disorders, 
increased cancer risk (Cornelius, 
2016) 
Cardiovascular: 
• Major cause of death in DM, 10x 
increase in death if heart rate over 
105bpm for over 5 minutes in the 
postoperative period (Cornelius, 
2016) 
• Increased risk of hypertension, 
coronary artery disease, CHF, silent 
myocardial ischemia, and 
peripheral vascular disease 
(McGinlay & Mruthunjaya, 2017) 
• Hyperglycemic states lead to 
“prothrombotic, proinflammatory, 
proatherogenic state and impairs 
vasodilation”  (Pontes, et al, 2017) 
Nephropathy: 
• CKD present in 40% of DM patients 
(Cornelius, 2016) 
• CKD leads to anemia, platelet 
dysfunction and albuminuria 
(Pones et al., 2017) 
Hepatic. 
• Fatty liver disease is closely related 
to DM and obesity, leading to the 
development of non-alcoholic 
chronic liver disease and 
hepatocellular cancers (McGinlay & 
Mruthunjaya, 2017) 
• Liver disease is one of the primary 
causes of death in DMII (Cornelius, 
2016) 
• Increased incidence of hepatitis B/C 
and hemochromatosis (Cornelius, 
2016) 
Immune System: 
• DM I has 15% increased incidence 
of other autoimmune disorders 
(Pontes et al., 2017) 
• Increased risk of hypothyroid, celiac 
disease, myasthenia gravis, and 
adrenal insufficiency (McGinlay & 
Mruthunjaya, 2017) 
Peripheral: 
• Peripheral neuropathy 
• Stiff joint Syndrome: “glycosylation 
of proteins and abnormal collage 
cross linking in joint” as a result of 
chronic hyperglycemia (Pontes et 
al., 2017) 
from chronic hyperglycemia 
increase risk of vomiting and 
aspiration (Pontes et al., 
2017) 
• IV starts may be difficult due 
to diabetic scleroderma 
(Cornelius, 2016) 
• Impaired blood flow may 
lead to delayed wound 
healing (Moningi et al., 2018) 
• DMI patients MUST receive 
insulin to meet basal 
metabolic needs and  prevent 
ketoacidosis  (Pontes et al., 
2017) 
• NSAIDs/COX inhibitors 
decrease renal blood flow 
and may cause edema.  Can 
cause acute renal failure or 
electrolyte imbalances 
(Pontes et al., 2017) 
Implications for 
Anesthetic Care 
• Perioperative mortality is 50% 
higher with DM and more likely for 
perioperative 
complications(reintubation, longer 
post operative ventilator time, need 
for resuscitation (Pontes et al., 
2017) 
• Hyperglycemia can cause intra/post 
operative:DKA, wound 
infections/delayed healing, HHNK 
(Cornelius, 2016) 
• Increased susceptibility to nerve 
injuries: increased risk with 
peripheral nerve blocks and 
vascular damage at block site 
(Moningi, 2018) 
• Stiff neck syndrome can cause 
reduced mobility in the cervical 
spine, leading to increased 
difficulties in intubation (Pontes et 
al., 2017) 
• Anesthesia can affect blood glucose 
via SNS tone: (Pontes et al., 2017) 
1. GABA agonists reduce cortisol 
secretion 
2. Clonidine reduces SNS and NE 
release 
3. Inhaled anesthetics inhibit insulin 
general anesthesia should 
not be taken lightly. 
There are many facets to 
consider 
• Discussions between the 
surgeon, anesthesia 
provider and the patient 
are paramount to discuss 
acceptable blood glucose 
both before and during 
surgery. 
• The successful 
management of DM and 
any complications allow 
for the best surgical 
outcome for the patient, 
not only the perioperative 
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